Outcomes | HS OHCA (n = 348) | p value | Non-HS OHCA (n = 161) | p value | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Time to epinephrine treatment | Time to epinephrine treatment | |||||||||
Total | Early (n = 88) | Middle (n = 205) | Late (n = 55) | Total | Early (n = 43) | Middle (n = 94) | Late (n = 24) | |||
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
Sustained ROSCa | 147 (42.4) | 48 (54.5) | 81 (39.5) | 18 (32.7) | 0.017 | 75 (46.6) | 30 (69.8) | 38 (40.4) | 7 (29.2) | 0.001 |
Survival to discharge | 36 (10.3) | 9 (10.2) | 22 (10.7) | 5 (9.1) | 0.938 | 24 (14.9) | 10 (23.3) | 12 (12.8) | 2 (8.3) | 0.172 |
Good neurological outcomesb | 7 (2.0) | 2 (2.3) | 4 (2.0) | 1 (1.8) | 0.978 | 8 (5.0) | 4 (9.3) | 3 (3.2) | 1 (4.2) | 0.305 |